Crude extract of Euphorbia formosana inhibits the migration and invasion of DU145 human prostate cancer cells: The role of matrix metalloproteinase-2/9 inhibition via the MAPK signaling pathway

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1403-1408

  Yang, Jiun Long ^a   Lin, Ju Hwa ^a   Weng, Shu Wen ^a,b   Chen, Jaw Chyun ^c   Yang, Jai Sing ^a   Amagaya, Sakae ^d   Funayana, Shinji ^d   Wood, W Gibson ^e   Kuo, Chao Lin ^a   Chung, Jing Gung ^a,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG HOSPITAL   (Taiwan)

^c DA YEH UNIVERSITY   (Taiwan)

^d NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Crude extract of Euphorbia formosana; DU145 human prostate cancer cells; MAPK signaling pathway; Migration; MMP 2; MMP 9

Indexed keywords

ANTINEOPLASTIC AGENT; EUPHORBIA EXTRACT; EUPHORBIA FORMOSANA EXTRACT; GELATINASE A; GELATINASE B; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SOS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; ENZYME ACTIVITY; ENZYME INHIBITION; EUPHORBIA; EUPHORBIA FORMOSANA; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; COMPLEX MIXTURES; EUPHORBIA; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EUPHORBIA;

EID: 84875968087     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1380     Document Type: Article

References (41)

1. Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann KU and Schostak M: Focal prostate cancer therapy: Capabilities, limitations and prospects. Urologe A: Oct 18, 2012 (Epub ahead of print) (In German).
2. Obertova Z, Brown C, Holmes M and Lawrenson R: Prostate cancer incidence and mortality in rural men - a systematic review of the literature. Rural Remote Health 12: 2039, 2012.
3. van der Meer S, Löwik SA, Hirdes WH, Nijman RM, Van der Meer K, Hoekstra-Weebers JE and Blanker MH: Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. BMC Fam Pract 13: 100, 2012.
4. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A and Berney DM: Staging of prostate cancer. Histopathology 60: 87-117, 2012.
5. Provenzano M: New biomarkers in prostate cancer. Praxis (Bern 1994) 101: 115-121, 2012 (In German).
6. Ou YC, Chen JT, Cheng CL, Ho HC and Yang CR: Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml. Jpn J Clin Oncol 33: 574-579, 2003.
7. Mener DJ: Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature. IUBMB Life 62: 584-590, 2010.
8. Roy M, Kung HJ and Ghosh PM: Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res 1: 542-561, 2011.
9. Zhang Y, Ma B and Fan Q: Mechanisms of breast cancer bone metastasis. Cancer Lett 292: 1-7, 2010.
10. Karakiewicz PI and Hutterer GC: Predictive models and prostate cancer. Nat Clin Pract Urol 5: 82-92, 2008.
11. Karlou M, Tzelepi V and Efstathiou E: Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 7: 494-509, 2010.
12. Khamis ZI, Iczkowski KA and Sang QX: Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med Res Rev 32: 1026-1077, 2012.
13. Minato N, Takada T, Koga M and Sugao H: Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report. Hinyokika Kiyo 58: 249-253, 2012 (In Japanese).
14. Payne H, Khan A, Chowdhury S and Davda R: Hormone therapy for radiorecurrent prostate cancer. World J Urol: Sep 21, 2012 (Epub ahead of print).
15. Smith BN and Odero-Marah VA: The role of Snail in prostate cancer. Cell Adh Migr 6: 433-441, 2012.
16. Hour MJ, Tsai SC, Wu HC, Lin MW, Chung JG, Wu JB, Chiang JH, Tsuzuki M and Yang JS: Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-κB and AP-1 signaling pathways in DU145 human prostate cancer cells. Int J Oncol: Jul 18, 2012 (Epub ahead of print).
17. Lee KH, Choi EY, Hyun MS and Kim JR: Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Exp Mol Med 36: 57-64, 2004.
18. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72: 1878-1889, 2012.
19. Guo LW, Gao L, Rothschild J, Su B and Gelman IH: Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12. J Biol Chem 286: 38356-38366, 2011.
20. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM and Jenster G: Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One 6: e23144, 2011.
21. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with alpha2-macroglobulin deficiency. Clin Lab 58: 217-225, 2012.
22. Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E and Leung HY: ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 104: 664-672, 2011.
23. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724, 2012.
24. Low JA, Johnson MD, Bone EA and Dickson RB: The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 2: 1207-1214, 1996.
25. Wojtowicz-Praga SM, Dickson RB and Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61-75, 1997.
26. Shinoda K, Shibuya M, Hibino S, Ono Y, Matsuda K, Takemura A, Zou D, Kokubo Y, Takechi A and Kudoh S: A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line. Int J Oncol 22: 281-288, 2003.
27. Yu CC, Hsieh CR, Hsiao G, Chen PY, Chang ML, Yin HW, Lee TH and Lee CK: Regulated expressions of MMP-2, -9 by diterpenoids from Euphorbia formosana Hayata. Molecules 17: 2082-2090, 2012.
28. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ and Chen CJ: Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study; R.E.V.E.A.L.-HCV Study Group: J Infect Dis 206: 469-477, 2012.
29. Lu CC, Yang JS, Chiang JH, Hour MJ, Amagaya S, Lu KW, Lin JP, Tang NY, Lee TH and Chung JG: Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling. Anticancer Res 32: 2895-2903, 2012.
30. Chen YY, Chiang SY, Lin JG, Ma YS, Liao CL, Weng SW, Lai TY and Chung JG: Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol 36: 1113-1120, 2010.
31. Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY, Yu CC and Chung JG: Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem 59: 9032-9038, 2011.
32. Hu WG, Li JW, Feng B, Beveridge M, Yue F, Lu AG, Ma JJ, Wang ML, Guo Y, Jin XL and Zheng MH: Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. Eur Surg Res 39: 229-238, 2007.
33. Ma D, Gerard RD, Li XY, Alizadeh H and Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738-2746, 1997.
34. Maarouf A, Adham M, Scoazec JY and Partensky C: Mixed hepato/cholangiocarcinoma with paraneoplastic hypercalcemia. J Hepatobiliary Pancreat Surg 15: 224-227, 2008.
35. Yang D, Gu T, Wang T, Tang Q and Ma C: Effects of osthole on migration and invasion in breast cancer cells. Biosci Biotechnol Biochem 74: 1430-1434, 2010.
36. Lin SS, Lai KC, Hsu SC, Yang JS, Kuo CL, Lin JP, Ma YS, Wu CC and Chung JG: Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett 285: 127-133, 2009.
37. Liu JW, Cai MX, Xin Y, Wu QS, Ma J, Yang P, Xie HY and Huang DS: Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res 29: 108, 2010.
38. Qin JM, Yin PH, Li Q, Sa ZQ, Sheng X, Yang L, Huang T, Zhang M, Gao KP, Chen QH, Ma JW and Shen HB: Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma. Int J Nanomedicine 7: 369-379, 2012.
39. Weigel MT, Kramer J, Schem C, Wenners A, Alkatout I, Jonat W, Maass N and Mundhenke C: Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 160: 74-78, 2012.
40. Zheng W, Zhang Y, Ma D, Shi Y, Liu C and Wang P: (+/-)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity. J Clin Biochem Nutr 51: 61-67, 2012.
41. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, Ma CY, Wood WG and Chung JG: Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett 279: 155-162, 2009.